Prostate Cancer Clinical Trial

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Summary

The purpose of this study is to test the safety and side effects "of "ultra-hypofractionated" radiation therapy when used after brachytherapy (radiation implants). This treatment delivers a higher radiation dose with each treatment over a shorter period of time.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as:
Pathologically-proven diagnosis of prostate adenocarcinoma
PSA 10-20ng/mL or
Gleason =7 or
Clinical stage T2b/c
Clinical stage T2b/c Additionally, patients will be required to meet the following criteria
Age ≥18
KPS≥70
Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician.
International Prostate Symptom Score ≤15

Exclusion Criteria:

Prior prostate surgery (including TURP)
Prior history of chronic prostatitis or urethral stricture
Inflammatory bowel disease
Prior history of pelvic radiotherapy
Unable to give informed consent
Metastatic disease.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

45

Study ID:

NCT02280356

Recruitment Status:

Completed

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Memorial Sloan Kettering at Basking Ridge
Basking Ridge New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack New York, 11725, United States
Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre New York, , United States
Memorial Sloan Kettering Nassau (Follow Up Only)
Uniondale New York, 11553, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

45

Study ID:

NCT02280356

Recruitment Status:

Completed

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.